United Therapeutics Management
Management criteria checks 3/4
United Therapeutics' CEO is Martine Rothblatt, appointed in Jan 1996, has a tenure of 28.25 years. total yearly compensation is $5.32M, comprised of 26.3% salary and 73.7% bonuses, including company stock and options. directly owns 1.37% of the company’s shares, worth $152.74M. The average tenure of the management team and the board of directors is 15 years and 21.5 years respectively.
Key information
Martine Rothblatt
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 26.3% |
| CEO tenure | 28.3yrs |
| CEO ownership | 1.4% |
| Management average tenure | 15yrs |
| Board average tenure | 21.5yrs |
Recent management updates
Recent updates
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05
United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17United Therapeutics reaches all-time high; shares up 15% YTD
Jul 06Why Hold United Therapeutics After Shares Doubled?
Jun 08With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Is Interesting
May 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Compensation vs Market: Martine's total compensation ($USD5.32M) is below average for companies of similar size in the US market ($USD13.51M).
Compensation vs Earnings: Martine's compensation has increased by more than 20% in the past year.
CEO
Martine Rothblatt (68 yo)
28.3yrs
Tenure
US$5,322,204
Compensation
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.3yrs | US$5.32m | 1.37% $ 152.7m | |
| President & COO | 7.8yrs | US$2.83m | 0.0052% $ 584.4k | |
| CFO & Treasurer | 11.3yrs | US$2.01m | 0.0031% $ 348.0k | |
| Executive VP | 28.3yrs | US$2.31m | 0.078% $ 8.7m | |
| Head of Investor Relations | no data | no data | no data | |
| Associate Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Strategic Operations & Logistics | no data | no data | no data | |
| Executive VP of Technical Operations | 15yrs | no data | no data | |
| Executive Vice President of Product Development & Xenotransplantation | no data | no data | no data | |
| Senior VP & Chief Medical Officer | no data | no data | no data |
15.0yrs
Average Tenure
55yo
Average Age
Experienced Management: UTHR's management team is seasoned and experienced (15 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 28.3yrs | US$5.32m | 1.37% $ 152.7m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 22.3yrs | US$485.37k | 0.024% $ 2.6m | |
| Independent Director & Member of the Scientific Advisory Board | 21.6yrs | US$515.37k | 0.028% $ 3.1m | |
| Independent Director & Member of the Scientific Advisory Board | 22.3yrs | US$495.35k | 0.0037% $ 414.9k | |
| Independent Vice Chairman & Lead Independent Director | 21.5yrs | US$562.98k | 0.0024% $ 262.1k | |
| Independent Director | 20.8yrs | US$520.35k | 0.0089% $ 991.5k | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 14.3yrs | US$500.37k | 0.048% $ 5.3m | |
| Member of the Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 15yrs | US$520.35k | 0.033% $ 3.7m | |
| Independent Director | 9.4yrs | US$485.37k | 0.0077% $ 863.2k |
21.5yrs
Average Tenure
75yo
Average Age
Experienced Board: UTHR's board of directors are seasoned and experienced ( 21.5 years average tenure).